Seroatlas · Human Serome Atlas

RRAD

GTP-binding protein RAD

Also known as: RAD, RAD_HUMAN, REM3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P55042
Gene: RRAD
Ensembl: ENSG00000166592
Chromosome: 16
Canonical length: 308 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Golgi apparatus,Plasma membrane,Flagellar centriole

OverviewNCBI Gene

Predicted to enable GTP binding activity and calcium channel regulator activity. Predicted to be involved in small GTPase-mediated signal transduction. Predicted to be located in T-tubule. Predicted to be active in plasma membrane. Implicated in type 2 diabetes mellitus. Biomarker of congestive heart failure. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

308 residues, UniProt reviewed canonical sequence.

>P55042|RRAD
     1  MTLNGGGSGA GGSRGGGQER ERRRGSTPWG PAPPLHRRSM PVDERDLQAA LTPGALTAAA
    61  AGTGTQGPRL DWPEDSEDSL SSGGSDSDES VYKVLLLGAP GVGKSALARI FGGVEDGPEA
   121  EAAGHTYDRS IVVDGEEASL MVYDIWEQDG GRWLPGHCMA MGDAYVIVYS VTDKGSFEKA
   181  SELRVQLRRA RQTDDVPIIL VGNKSDLVRS REVSVDEGRA CAVVFDCKFI ETSAALHHNV
   241  QALFEGVVRQ IRLRRDSKEA NARRQAGTRR RESLGKKAKR FLGRIVARNS RKMAFRAKSK
   301  SCHDLSVL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RRAD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 777 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 777 nTPM
heart muscle: 316 nTPM
blood vessel: 111 nTPM
esophagus: 104 nTPM
adipose tissue: 58 nTPM
lung: 52 nTPM

Single-cell type

thymic myoid cells: 585 nCPM
respiratory ciliated cells: 557 nCPM
fallopian tube ciliated cells: 549 nCPM
endometrial ciliated cells: 512 nCPM
endometrial luminal cells: 480 nCPM
vascular smooth muscle cells: 438 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 31 nTPM
cerebral cortex: 25 nTPM
choroid plexus: 22 nTPM
basal ganglia: 9.6 nTPM
white matter: 9 nTPM
midbrain: 8.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.65
gnomAD pLI: 0.44
gnomAD missense Z: 1.11
DepMap mean gene effect: -0.19
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

small GTPase-mediated signal transduction

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RRAD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RRAD as an antibody target. Whether an autoantibody or antibody against RRAD could matter depends on whether native RRAD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RRAD is annotated at the cell surface, where native RRAD is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label RRAD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...